A citation-based method for searching scientific literature

David Blum, Yijuang Chern, Maria Rosaria Domenici, Luc Buée, Chien-Yu Lin, William Rea, Sergi Ferré, Patrizia Popoli. J Caffeine Adenosine Res 2018
Times Cited: 25







List of co-cited articles
337 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pharmacology of Adenosine Receptors: The State of the Art.
Pier Andrea Borea, Stefania Gessi, Stefania Merighi, Fabrizio Vincenzi, Katia Varani. Physiol Rev 2018
312
28


Association between caffeine intake and age at onset in Huntington's disease.
Clémence Simonin, Cécile Duru, Julia Salleron, Pascale Hincker, Perrine Charles, Arnaud Delval, Katia Youssov, Sylvie Burnouf, Jean-Philippe Azulay, Christophe Verny,[...]. Neurobiol Dis 2013
40
24

CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
Szu-Yi Chou, Yi-Chao Lee, Hui-Mei Chen, Ming-Chang Chiang, Hsing-Lin Lai, Hao-Hung Chang, Yi-Chih Wu, Chung-Nan Sun, Chen-Li Chien, Yow-Sien Lin,[...]. J Neurochem 2005
143
24

Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Wei Li, Henrique B Silva, Joana Real, Yu-Mei Wang, Daniel Rial, Ping Li, Marie-Pierce Payen, Yuanguo Zhou, Christa E Muller, Angelo R Tomé,[...]. Neurobiol Dis 2015
70
20


A new drug design targeting the adenosinergic system for Huntington's disease.
Nai-Kuei Huang, Jung-Hsin Lin, Jiun-Tsai Lin, Chia-I Lin, Eric Minwei Liu, Chun-Jung Lin, Wan-Ping Chen, Yuh-Chiang Shen, Hui-Mei Chen, Jhih-Bin Chen,[...]. PLoS One 2011
59
20

Adenosine receptors and Huntington's disease.
Chien-fei Lee, Yijuang Chern. Int Rev Neurobiol 2014
26
20

The A3 adenosine receptor: history and perspectives.
Pier Andrea Borea, Katia Varani, Fabrizio Vincenzi, Pier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Stefania Merighi, Stefania Gessi. Pharmacol Rev 2015
167
20

Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?
Pier Andrea Borea, Stefania Gessi, Stefania Merighi, Katia Varani. Trends Pharmacol Sci 2016
173
20

Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease.
Andreas Matusch, Carsten Saft, David Elmenhorst, Peter H Kraus, Ralf Gold, Hans-Peter Hartung, Andreas Bauer. Eur J Nucl Med Mol Imaging 2014
20
25


Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
L Mangiarini, K Sathasivam, M Seller, B Cozens, A Harper, C Hetherington, M Lawton, Y Trottier, H Lehrach, S W Davies,[...]. Cell 1996
16

Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
Xavier Guitart, Jordi Bonaventura, William Rea, Marco Orrú, Lucrezia Cellai, Ilaria Dettori, Felicita Pedata, Marc Brugarolas, Antonio Cortés, Vicent Casadó,[...]. Neurobiol Dis 2016
17
23

Neuronal adenosine A2A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease.
Maria Rosaria Domenici, Valentina Chiodi, Mirko Averna, Monica Armida, Antonella Pèzzola, Rita Pepponi, Antonella Ferrante, Michael Bader, Kjell Fuxe, Patrizia Popoli. Purinergic Signal 2018
8
50

Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
Yu-Han Kao, Meng-Syuan Lin, Chiung-Mei Chen, Yih-Ru Wu, Hui-Mei Chen, Hsing-Lin Lai, Yijuang Chern, Chun-Jung Lin. Hum Mol Genet 2017
26
16

Huntington's disease: a clinical review.
P McColgan, S J Tabrizi. Eur J Neurol 2018
374
16

A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.
C Laurent, S Burnouf, B Ferry, V L Batalha, J E Coelho, Y Baqi, E Malik, E Mariciniak, S Parrot, A Van der Jeugd,[...]. Mol Psychiatry 2016
97
16

Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors.
Mariana Temido-Ferreira, Diana G Ferreira, Vânia L Batalha, Inês Marques-Morgado, Joana E Coelho, Pedro Pereira, Rui Gomes, Andreia Pinto, Sara Carvalho, Paula M Canas,[...]. Mol Psychiatry 2020
80
16


The neuroprotective effects of caffeine in neurodegenerative diseases.
Mahshad Kolahdouzan, Mazen J Hamadeh. CNS Neurosci Ther 2017
104
16

Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.
B B Fredholm, K Bättig, J Holmén, A Nehlig, E E Zvartau. Pharmacol Rev 1999
16

A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis.
Shigeki Tsutsui, Jurgen Schnermann, Farshid Noorbakhsh, Scot Henry, V Wee Yong, Brent W Winston, Kenneth Warren, Christopher Power. J Neurosci 2004
244
16

Pathological overproduction: the bad side of adenosine.
Pier Andrea Borea, Stefania Gessi, Stefania Merighi, Fabrizio Vincenzi, Katia Varani. Br J Pharmacol 2017
65
16

Adenosine receptors as drug targets--what are the challenges?
Jiang-Fan Chen, Holger K Eltzschig, Bertil B Fredholm. Nat Rev Drug Discov 2013
555
16

Huntington disease.
Gillian P Bates, Ray Dorsey, James F Gusella, Michael R Hayden, Chris Kay, Blair R Leavitt, Martha Nance, Christopher A Ross, Rachael I Scahill, Ronald Wetzel,[...]. Nat Rev Dis Primers 2015
682
16

Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Antonella Ferrante, Alberto Martire, Rita Pepponi, Katia Varani, Fabrizio Vincenzi, Luca Ferraro, Sarah Beggiato, Maria Teresa Tebano, Patrizia Popoli. Neurobiol Dis 2014
19
21

Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors.
Ana M Sebastião, Nádia Rei, Joaquim A Ribeiro. Front Pharmacol 2018
15
26

Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.
Liliana B Menalled, Andrea E Kudwa, Sam Miller, Jon Fitzpatrick, Judy Watson-Johnson, Nicole Keating, Melinda Ruiz, Richard Mushlin, William Alosio, Kristi McConnell,[...]. PLoS One 2012
245
12

Purinergic signaling in Parkinson's disease. Relevance for treatment.
Gemma Navarro, Dasiel O Borroto-Escuela, Kjell Fuxe, Rafael Franco. Neuropharmacology 2016
48
12

Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.
Joan Lindsay, Danielle Laurin, René Verreault, Réjean Hébert, Barbara Helliwell, Gerry B Hill, Ian McDowell. Am J Epidemiol 2002
807
12

Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress.
Manuella P Kaster, Nuno J Machado, Henrique B Silva, Ana Nunes, Ana Paula Ardais, Magda Santana, Younis Baqi, Christa E Müller, Ana Lúcia S Rodrigues, Lisiane O Porciúncula,[...]. Proc Natl Acad Sci U S A 2015
185
12

Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia.
Izaskun Villar-Menéndez, Sara Díaz-Sánchez, Marta Blanch, José Luis Albasanz, Thais Pereira-Veiga, Alfonso Monje, Luis Maria Planchat, Isidre Ferrer, Mairena Martín, Marta Barrachina. J Psychiatr Res 2014
30
12

Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors.
Silvia Viana da Silva, Matthias Georg Haberl, Pei Zhang, Philipp Bethge, Cristina Lemos, Nélio Gonçalves, Adam Gorlewicz, Meryl Malezieux, Francisco Q Gonçalves, Noëlle Grosjean,[...]. Nat Commun 2016
139
12

The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
Ming-Chang Chiang, Hui-Mei Chen, Hsing-Lin Lai, Hsiao-Wen Chen, Szu-Yi Chou, Chiung-Mei Chen, Fuu-Jen Tsai, Yijuang Chern. Hum Mol Genet 2009
59
12

Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
M R Domenici, M L Scattoni, A Martire, G Lastoria, R L Potenza, A Borioni, A Venerosi, G Calamandrei, P Popoli. Neurobiol Dis 2007
50
12

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.
Bertil B Fredholm, Adriaan P IJzerman, Kenneth A Jacobson, Joel Linden, Christa E Müller. Pharmacol Rev 2011
928
12

Enhanced role of adenosine A(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing.
Ana R Costenla, Maria J Diógenes, Paula M Canas, Ricardo J Rodrigues, Célia Nogueira, João Maroco, Paula M Agostinho, Joaquim A Ribeiro, Rodrigo A Cunha, Alexandre de Mendonça. Eur J Neurosci 2011
108
12

Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.
Chia-Chia Lee, Ching-Pang Chang, Chun-Jung Lin, Hsing-Lin Lai, Yu-Han Kao, Sin-Jhong Cheng, Hui-Mei Chen, Yu-Ping Liao, Emilie Faivre, Luc Buée,[...]. Mol Neurobiol 2018
31
12

Adenosine receptor neurobiology: overview.
Jiang-Fan Chen, Chien-fei Lee, Yijuang Chern. Int Rev Neurobiol 2014
80
12


Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway.
Paula M Canas, Lisiane O Porciúncula, Geanne M A Cunha, Carla G Silva, Nuno J Machado, Jorge M A Oliveira, Catarina R Oliveira, Rodrigo A Cunha. J Neurosci 2009
251
12

Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease.
José L Albasanz, Sandra Perez, Marta Barrachina, Isidro Ferrer, Mairena Martín. Brain Pathol 2008
120
12

Caffeine as a protective factor in dementia and Alzheimer's disease.
Marjo H Eskelinen, Miia Kivipelto. J Alzheimers Dis 2010
130
12


Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
J Ingwersen, B Wingerath, J Graf, K Lepka, M Hofrichter, F Schröter, F Wedekind, A Bauer, J Schrader, H-P Hartung,[...]. J Neuroinflammation 2016
57
12

International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.
B B Fredholm, A P IJzerman, K A Jacobson, K N Klotz, J Linden. Pharmacol Rev 2001
12


Structure and function of adenosine receptors and their genes.
B B Fredholm, G Arslan, L Halldner, B Kull, G Schulte, W Wasserman. Naunyn Schmiedebergs Arch Pharmacol 2000
442
12

A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation.
Ester Angulo, Vicent Casadó, Josefa Mallol, Enric I Canela, Francesc Viñals, Isidre Ferrer, Carmen Lluis, Rafael Franco. Brain Pathol 2003
118
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.